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A B S T R A C T
Receptor for advanced glycation end products (RAGE) plays a role in atherosclerosis
in diabetics. There are two functional polymorphisms in the promoter of the RAGE gene
(–429T/C and –374T/A). The aim of this study was to look for a relationship between the
–429T/C and the –374T/A gene polymorphisms of the RAGE gene and the development of
coronary artery disease (CAD) in the Slovene population with type 2 diabetes of duration
longer than 10 years. One hundred and sixty-eight subjects with diabetes and CAD were
compared to 241 diabetic subjects without CAD. The –429T/C and the –374T/A RAGE
genotype distributions in patients with CAD (–429T/C: CC: 3%, TC: 31%, TT: 66.0%;
–374T/A: AA: 7.7%, TA: 48.2%, TT: 44.1%) were not significantly different from those in
patients without CAD (–429 T/C: CC: 1.7%, TC: 26.1%, TT: 72.2%; –374T/A: AA: 11.2%,
TA: 43.2%, TT: 45.6%). Our study failed to demonstrate an association between either
the –429T/C or the –374T/A gene polymorphism of the RAGE gene and CAD in the Slo-
vene population with type 2 diabetes of duration longer than 10 years.
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Introduction
The prevalence of type 2 diabetes has
been increasing worldwide due to increa-
sing obesity and decreasing physical acti-
vity1. In people with type 2 diabetes the
leading cause of death is coronary artery
disease (CAD)1. Several candidate genes
for CAD such as the angiotensin-1 con-
verting enzyme (ACE) gene, plasminogen
activator inhibitor gene, apoprotein E ge-
ne, apoprotein A1 gene, estrogen receptor
gene, and the hemochromatosis gene ha-
ve so far been tested in the Slovene popu-
lation, whereas the receptor for advanced
glycation end products (RAGE) is another
candidate gene for CAD that has not been
tested in the Slovene population yet2–10.
So far, one the DD genotype of the inser-
tion/deletion gene polymorphism of the
ACE gene has been demonstrated to be a
genetic risk factor for CAD in Slovene po-
pulation.
The RAGE is normally expressed at
low levels in the vasculature, whereas it
is over-expressed in the vessel wall in the
presence of vascular diseases11. The RAGE
has been implicated in the development
of vascular complications of diabetes by
both in vitro and in vivo studies12. Evi-
dence to implicate the RAGE is provided
by the beneficial effect the soluble RAGE
has on the development of vascular di-
seases13, as well as the demonstration of
increased expression in diseased vascular
tissues of diabetic animal models and hu-
man subjects14,15. The hyperglycemic mi-
lieu in diabetes results in the accelerated
formation of advanced glycation end prod-
ucts (AGEs); the effects of AGEs have
been shown to be mediated via various
cellular receptors (macrophage scavenger
receptor, LOX-1, OST 48, and PRKCSH)16.
One of the most important receptor is the
RAGE16,17. Activation of the RAGE via
AGEs stimulates proinflammatory and
procoagulatory pathways leading to vascu-
lar dysfunction12,18. The RAGE, AGEs and
proinflammatory ligands are implicated
in the pathogenesis of atherosclerosis12,18.
Two functional polymorphisms in the pro-
moter of the RAGE gene (–429 T/C and
–374 T/A) that may be important in the
pathogenesis of diabetic vascular disea-
ses have recently been described19,20.
The aim of this study was to look for a
relationship between the –429 T/C and
–374 T/Agene polymorphisms of the RAGE
and the development of CAD in the Slove-
ne population with type 2 diabetes of du-
ration longer than 10 years.
Materials and Methods
Patients
The study population of this cross-sec-
tional case-control association study con-
sisted of 409 diabetic subjects with type 2
diabetes of duration longer than 10 years.
In the CAD group (168 cases) 130 cases
with a history of myocardial infarction
(MI) (the diagnosis of MI was made accor-
ding to the criteria by World Health Or-
ganization) and 38 cases with angina pec-
toris confirmed by either abnormal stress
testing or abnormal perfusion scan21. The
patients and diabetic control subjects ca-
me from independent families. The data
and blood samples of patients with CAD
and diabetic control subjects were obtai-
ned from the Diabetic Outpatient Clinic
and the Eye Clinic of the University Med-
ical Centre Ljubljana, and from general
practitioners. The diabetic control group
consisted of 241 diabetics with no history
of CAD, no signs of ischemic changes on
electrocardiogram and no ischemic chan-
ges during submaximal stress testing. All
the subjects enrolled in the study were
Slovene. The research protocol was ap-
proved by the national medical ethics
committee. After informed consent was
obtained from the patients and diabetic
control subjects, a detailed interview was
made. The physician interviewed each
patient and diabetic control subject about
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the coronary risk factors (cigarette smok-
ing, arterial hypertension, body weight
and height). Smoking habit was defined
as a daily intake of more than 5 cigaret-
tes. Arterial hypertension was measured
ambulatory, and was defined as a binary
variable. Arterial hypertension was defi-
ned as systolic blood pressure higher
than 140 mmHg, diastolic blood pressure
higher than 90 mm Hg, or both, at repea-
ted measurements, or current use of anti-
hypertensive agents for the confirmed di-
agnosis of arterial hypertension. Patients
were classified as having type 2 diabetes
according to the current American Diabe-
tic Association criteria for the diagnosis
and classification of diabetes22.
Total cholesterol, low density lipopro-
teins (LDL), high density lipoproteins
(HDL) and triglycerides were determined
by standard biochemical methods21
Genotyping
The –429 T/C and –374 T/A gene poly-
morphisms of the RAGE gene were geno-
typed by PCR-RFLP, using primers: –429
T/C (5’-TTTCTTTCACGAAGT/CTCCA-
AACAGGTTTC-3’) and –374 T/A (5’-AT-
GCAGGCCCAAT/ATGCACCCTTGCA
GA-3’) followed by Alu I and Tsp 509 I
restriction19. Genotyping was done by two
researchers (AM@, KS), blinded to the di-
sease status of the subjects with type 2
diabetes.
Statistics
Differences in mean values were ana-
lyzed by unpaired Student’s t-test and
presented as means ± standard deviation
(SD). Chi-square test was used to compa-
re discrete variables and genotype distri-
butions. Genotypic odds ratios (OR) for
CAD with 95% confidence intervals with
two-tailed p values were calculated by
multiple logistic regression analysis ad-
justed for cardiovascular risk factors
(smoking, sex, LDL cholesterol, diastolic
blood pressure, duration of diabetes, body
mass index (BMI), –374 T/A gene poly-
morphism, –429 T/C gene polymorphism,
age). Statistical analysis was performed
using the SPSS program for Windows
version 11 (SPSS Inc. Illinois).
Results
One hundred and sixty-eight diabetics
with CAD were compared with 241 diabe-
tics without CAD. The characteristics of
the cases and control subjects are listed
in Table 1. A higher frequency of cigarette
smoking and male sex were registered in
the CAD than in the diabetic control
group. The cases had longer duration of
diabetes, higher BMI and lower diastolic
blood pressure, a higher total cholesterol
level, a higher LDL cholesterol level and
a lower HDL cholesterol level than the
controls (Table 1).
The genotype distributions of the –429
T/C and –374 T/A gene polymorphisms of
the RAGE in cases and controls were
compatible with Hardy-Weinberg expec-
tations. There were no differences either
in the frequencies of the genotypes of the
–429 T/C gene polymorphism or in the
frequencies of the genotypes of the –374
T/A gene polymorphism of the RAGE ge-
ne between the patients with CAD and
those without it (Table 2). Subgroup anal-
yses in males and females also failed to
demonstrate any significant differences
either in the frequencies of the genotypes
of the –429 T/C gene polymorphism or in
the frequencies of the genotypes of the
–374 T/A gene polymorphism of the RAGE
gene between the patients with CAD and
those without it (data not shown). Moreo-
ver, there were no statistically significant
differences either in the frequencies of
the alleles of the –429 T/C gene polymor-
phism (cases: allele C 18.4 %, allele T
81.6 %, controls: allele C 14.7 %, allele T
85.3 %) and/or in the frequencies of the
alleles of the –374 T/A gene polymorphi-
sm (cases: allele A 31.8 %, allele T 68.2 %,
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controls: allele A 32.8 %, allele T 67.2 %)
of the RAGE gene between the patients
with CAD and those without it.
Multiple logistic regression analysis
showed that the duration of diabetes was
the only independent risk factor for CAD
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TABLE 1
CLINICAL CHARACTERISTICS OF TYPE 2 DIABETIC PATIENTS






Age (years) 59.3 ± 11.4 66.9 ± 9.6 <0.001
Male sex (%) 109 (64.90) 104 (43.2) <0.001
Duration of diabetes (years) 21.8 ± 7.4 17.8 ± 8.4 0.002
Insulin therapy 114 (67.8) 140 (58.1) 0.4
Age of onset of diabetes 49.6 ± 10.2 49.2 ± 10.9 0.8
HbA1c (%) 8.4 ± 1.6 8.0 ± 1.7 0.2
Systolic blood pressure (mm Hg) 146 ± 20 145 ± 24 0.5
Diastolic blood pressure (mm Hg) 83 ± 10 85 ± 10 0.02
BMI (kg/m2) 28.7 ± 3.7 27.8 ± 4.5 0.05
History of hypertension (%) 115 (68.5) 162 (67.2) 0.8
Smokers (%) 74 (44.0) 34 (14.1) <0.001
Total cholesterol (mmol/l) 5.8 ± 1.5 5.5 ± 1.3 0.03
HDL cholesterol (mmol/l) 1.1 ± 0.3 1.2 ± 0.4 0.04
LDL cholesterol (mmol/l) 3.7 ± 1.4 3.2 ± 1.0 0.001
Triglycerides (mmol/l) 2.4 ± 1.3 2.5 ± 1.7 0.5
TABLE 2
GENOTYPE DISTRIBUTIONS OF THE –374 T/A (p VALUE = 0.4, CHI SQUARE = 1.8) AND THE
–429 T/C A (p VALUE = 0.3, CHI SQUARE = 2.1) GENE POLYMORPHISM OF THE RAGE GENE






OR (95 % CI)1 p value
–374 T/A
AA genotype 13 (7.7) 27 (11.2) 0.7 (0.3–1.3)2 0.32
TA genotype 81 (48.2) 104 (43.2) 1.1 (0.7–1.6)3 0.73
TT genotype 74 (44.1) 110 (45.6)
–429 T/C
CC genotype 5 (3.0) 4 (1.7) 1.8 (0.5–6.9)4 0.44
TC genotype 52 (31.0) 63 (26.1) 1.3 (0.9–2.0)5 0.25
TT genotype 111 (66.0) 174 (72.2)
1Odds ratio (95% confidence interval)
2Odds ratio (95% confidence interval) and P-value for recessive model (AA vs. TA plus TT)
3Odds ratio (95% confidence interval) and P-value for dominant model (AA plus TA vs. TT)
4Odds ratio (95% confidence interval) and P-value for recessive model (CC vs. TC plus TT)
5Odds ratio (95% confidence interval) and P-value for dominant model (CC plus TC vs. TT).
in type 2 diabetes (OR = 0.95 95% CI =
0.90–1.0; P = 0.04), whereas –429 T/C and
–374 T/A gene polymorphisms as well as
other variables in the logistic model were
not.
Discussion
Our study failed to demonstrate an as-
sociation between either the –429 T/C or
the –374 T/A gene polymorphism of the
RAGE gene and CAD in the Slovene pop-
ulation with type 2 diabetes of duration
longer than 10 years.
The cardiovascular complications of
diabetes represent the leading cause of
morbidity and mortality in affected sub-
jects. Beside environmental factors, gene-
tic factors including the gene polymor-
phism of the RAGE are implicated in the
pathogenesis of macrovascular and mic-
rovascular complications of diabetes12,19,20.
Hudson with collaborators demonstrated
an effect of the –429 T/C or the –374 T/A
gene polymorphism on gene expression,
which indicated an influence on RAGE le-
vels19. A significant association between
the –429 T/C gene polymorphism of the
RAGE and diabetic retinopathy was re-
ported in a group of Caucasians with type
2 diabetes, but this association was not
confirmed in another group of Caucasians
with type 2 diabetes19,23.
Pettersson-Fernholm with collabora-
tors examined the association between
the two functional polymorphisms in the
promoter of the RAGE gene (–429 T/C
and –374 T/A) and CAD in 996 Finnish
patients with type 1 diabetes20. In patients
with the –374 AA genotype they observed
less CAD, and fewer acute myocardial in-
farctions and peripheral vascular disea-
ses than in those with the TT + TA geno-
types. In our study, however, we failed to
demonstrate an association between eit-
her the –374 T/A or –429 T/C gene poly-
morphism of the RAGE gene and CAD in
409 Slovenes with type 2 diabetes lasting
longer than 10 years. We presume that
the lack of relationship between these po-
lymorphisms and CAD in our study may
be due to multifactorial nature of the dis-
ease, population bias, or sample size.
These polymorphisms may make either
little or no detectable contribution to
CAD. Another explanation for the negati-
ve result of an association study might be
a type 2 statistical error (i.e., failing to re-
ject the null hypothesis – that there is no
difference in genotype distribution be-
tween the two groups when it is false).
One way to circumvent this problem is to
increase the study sample. Moreover, ot-
her reasons for differences between our
study and the Finish study reported by
Pettersson-Fernholm might be that Fin-
ish subjects with type 1 diabetes had lon-
ger duration of diabetes (more than 20
years) in comparison with our study (mo-
re than 10 years); besides, they were much
younger than the subjects in our study20.
In conclusion, we failed to demonstra-
te an association between either the –429
T/C or the –374 T/A gene polymorphism
of the receptor of advanced glycation end
products gene and CAD in the Slovene
population with type 2 diabetes of dura-
tion longer than 10 years.
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GENETSKI POLIMORFIZMI –429 T/C I –374 T/A RECEPTORA
ZA PRODUKT KRAJNJE GLIKOZILACIJE (RAGE) NISU ^IMBENICI
RIZIKA ZA KORONARNU BOLEST SRCA KOD SLOVENSKE
POPULACIJE S DIABETESOM TIPA 2
S A @ E T A K
Receptor za produkt napredne glikozilacije (RAGE) ima ulogu u stvaranju ateros-
kleroze kod dijabeti~ara. Postoje dva polimorfizma u promotoru RAGE gena (–429T/C i
–374T/A). Cilj ovog rada bio je prona}i vezu izme|u–429T/C i –374T/A polimorfizma i
razvoja koronarne bolesti srca (KBS) u populaciji bolesnika s diabetesom tip 2 u Slove-
niji. 168 bolesnika s diabetesom i koronarnom bolesti je uspore|eno s 241 bolesnikom s
diabetesom ali bez koronarne bolesti srca. –429T/C i –374T/A RAGE distribucije geno-
tipa kod bolesnika s KBS (–429T/C: CC: 3%, TC: 31%, TT: 66.0%; –374T/A: AA: 7.7%,
TA: 48.2%, TT: 44.1%) nisu se zna~ajno razlikovale od onih kod bolesnika bez KBS
(–429 T/C: CC: 1.7%, TC: 26.1%, TT: 72.2%; –374T/A: AA: 11.2%, TA: 43.2%, TT: 45.6%).
Ova studija nije pokazala zna~ajnu vezu izme|u–429T/C ili –374T/A polimorfizma
RAGE gena i koronarne bolesti srca me|u bolesnicima s trajanjem diabetesa tip 2 ve-
}im od 10 godina u Sloveniji.
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